Combination of lamivudine and adefovir without hepatitis B immune globulin is safe and effective prophylaxis against hepatitis B virus recurrence in hepatitis B surface antigen-positive liver transplant candidates. [electronic resource]
Producer: 20130903Description: 268-74 p. digitalISSN:- 1527-6473
- Adenine -- administration & dosage
- Adult
- Aged
- Antiviral Agents -- administration & dosage
- Biomarkers -- blood
- DNA, Viral -- blood
- Disease-Free Survival
- Drug Therapy, Combination
- Female
- Hepatitis B -- blood
- Hepatitis B Surface Antigens -- blood
- Hepatitis B virus -- genetics
- Humans
- Immunoglobulins -- administration & dosage
- Kaplan-Meier Estimate
- Lamivudine -- administration & dosage
- Liver Transplantation -- adverse effects
- Male
- Middle Aged
- New South Wales
- New Zealand
- Organophosphonates -- administration & dosage
- Prospective Studies
- Risk Factors
- Secondary Prevention
- Time Factors
- Treatment Outcome
- Victoria
- Viral Load
- Young Adult
No physical items for this record
Publication Type: Clinical Trial; Journal Article; Multicenter Study
There are no comments on this title.
Log in to your account to post a comment.